Ушбу ишга иқтибос қилган ишлар

2 та иш

Иш: A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.

1. Development of criteria for the selection of therapeutic effects on metastatic renal cell carcinoma considering the factors of tumor microenvironment.

   M.N. Tillyashaykhov, Tashkent, Uzbekistan, E.V. Boyko +3

   МақолаRenal cell carcinoma treatmentExperimental and Сlinical Urology20230 иқтибос

   ABIABI:AkademIndex/openalex/2023.article.006571

2. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment

   Saade Abdalkareem Jasim, I.M. Farber, Sara Abdalrazzaq M. Noraldeen +7

   МақолаAngiogenesis and VEGF in CancerMicrovascular Research20240 иқтибос

   ABIABI:AkademIndex/openalex/2024.article.003439